ENTA
USDEnanta Pharmaceuticals Inc. Common Stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$7.565
고가
$8.470
저가
$7.475
거래량
0.24M
기업 기본 정보
시가총액
169.9M
산업
생명공학
국가
United States
거래 통계
평균 거래량
0.20M
거래소
NMS
통화
USD
52주 범위
관련 뉴스
Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
MAVYRET® (glecaprevir/pibrentasvir) is Now the Only Direct Acting Antiviral Therapy Approved to Treat Patients with Acute Hepatitis C Virus (HCV) in Eight Weeks with a 96% Cure Rate1*† FDA Approval Now
JMP Securities Maintains Market Outperform on Enanta Pharma, Raises Price Target to $24
JMP Securities analyst Roy Buchanan maintains Enanta Pharma with a Market Outperform and raises the price target from $23 to $24.
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D.,
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's
관련 주식
최신 정보 받기
가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기